search

Active clinical trials for "Hyperlipidemias"

Results 591-600 of 695

Supplementation of Oil Palm Phenolics to Healthy Participants

Cardiovascular DiseasesHyperlipidemias1 more

Our previous study has found that oil palm phenolics (OPP) supplementation at 9 grams per day is safe for consumption. An interesting observation was reported where the consumption of OPP showed significantly lower total and LDL cholesterol compared to the control group. There is no clinical evidence as yet on the optimum dosage of OPP supplementation in improving fasting lipid profile. We hypothesize that in a clinical study, OPP supplemented participants will elicit a reduction in total and LDL cholesterol while maintaining safety and tolerability.

Unknown status10 enrollment criteria

Plasma Mannose Associated Parameter Levels in Nondiabetic Coronary Artery Disease

Coronary Artery DiseaseHyperlipidemias

Aims: Nondiabetic patients have been studied to determine whether modest elevations in plasma mannose levels may be associated with a greater incidence of coronary artery disease (CAD). Methods: The plasma mannose, lipids (triglyceride, LDL, HDL, LDL, VLDL) and LDH levels were successfully will be evaluated with respect to subsequent coronary artery disease using records 120 nondiabetic patients and 120 healthy volunteers. CAD was identified from myocardial infarction and new diagnoses of angina. The associations between mannose levels and serum lipid parameters will be investigated.

Completed5 enrollment criteria

Nutritional Intervention With Black Garlic

HypercholesterolemiaHypertension3 more

A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease. Black garlic is the result of a fermentation process of common white garlic in which the temperature and humidity are kept constant over a long period of time. Black garlic is particularly rich in phenolic compounds such as S-allylcysteine or S-allyl-mercaptocysteine, with antioxidant action. It also provides vitamin C and other valuable antioxidant substances such as flavonoids.

Unknown status11 enrollment criteria

Gender Dependent Difference in Lipemia After 6 x OFTT in Young Healthy Subjects

Hyperlipidemia

The investigators wanted to study the postprandial lipemia after six oral fat tolerance test with varying amounts of saturated fat in young healthy subjects.

Completed6 enrollment criteria

Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects

HyperlipidemiaHypertension

The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan co-administration and Livalo fixed combination drug in healthy male subjects.

Completed4 enrollment criteria

Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters

Hyperlipidemia

The purpose of this study is to evaluate the safety and efficacy of long-term use of granular capsule formulation of omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in patients with hyperlipidemia in daily medical practice

Completed3 enrollment criteria

Effects of Hypolipemic Treatment on Adipokines

HyperlipidemiaImpaired Fasting Glycemia

The study is planned to show whether monotherapies or combined hypolipemic therapy influence the fasting plasma glucose, serum adipokines (leptin, adiponectin, resistin) and proinflammatory cytokines (interleukin-6, TNF alpha) during 30 and 90 day course.

Completed27 enrollment criteria

Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects

HyperlipidemiaHypertension

The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan co-administration and Livalo fixed combination drug in healthy male subjects.

Completed4 enrollment criteria

Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production...

Hyperlipidemia

Recent studies in both animals and humans has demonstrated that the hormone GLP-1 (glucagon like peptide 1) reduces intestinal production of lipoprotein particles. The investigators therefore hypothesise that the drug sitagliptin which prevents the breakdown of GLP-1 will reduce intestinal lipoprotein production in humans. The investigators are unable to speculate whether sitagliptin will affect hepatic lipoprotein production because of lack of of data from animal studies or in vitro data. Sitagliptin is already an approved treatment for type 2 diabetes.

Completed14 enrollment criteria

Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

The role of hyperlipidemia and lipid lowering therapy (LLT) in Amyotrophic Lateral Sclerosis (ALS) pathophysiology and its impact on disease progression and survival is unclear. The investigators analyzed the correlation between lipid levels with disease progression and survival in ALS patients and the association of LLT with these outcomes.

Completed8 enrollment criteria
1...596061...70

Need Help? Contact our team!


We'll reach out to this number within 24 hrs